Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Legend Biotech Q2 EPS $(0.05) Beats $(0.38) Estimate, Sales $186.52M Beat $126.59M Estimate

Author: Benzinga Newsdesk | August 09, 2024 07:04am
Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.38) by 86.84 percent. This is a 91.23 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $186.52 million which beat the analyst consensus estimate of $126.59 million by 47.34 percent. This is a 154.36 percent increase over sales of $73.33 million the same period last year.

Posted In: LEGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist